Aggrenox®

References

PubMed
  1. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. BMJ 1969; 1: 614-615.
  2. Adams GA, Feuerstein IA. Platelet accumulation on collagen: drugs which inhibit arachidonic acid metabolism and affect intracellular cyclic AMP levels. Thromb Haemost 1984; 52: 45-49.
  3. Adams et al. Stroke 2008; 39: 1647-1652
  4. Adams et al. Stroke 2008 [Epub ahead of print].
  5. Aktas et al. Stroke 2003; 34: 764–769
  6. Albers GW, Easton JD, Sacco RL, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114 (Suppl 5): 683S-698S.
  7. Albers, Tijssen. Neurology 1999; 53 (7 Suppl 4): S25–S31.
  8. Albers. Neurology 2000; 54: 1022–1028.
  9. Albers et al. Chest 2001; 119: 300S-320S.
  10. Albers et al. Chest 2004; 126 (3 Suppl): 438S–512S.
  11. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-199.
  12. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1998.
  13. The American-Canadian Co-operative Study Group. Persantine Aspirin Trial in cerebral ischemia: part II: endpoint results. Stroke 1985; 16: 406-415.
  14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
  15. Bhatt et al. Am Heart J 2004; 148 (2): 263-268.
  16. Bhatt et al. The Main Results of the CHARISMA Trial. Oral Presentation 402-10. ACC 2006. March 12th, 2006
  17. Bhatt et al. N Eng J Med 2006; 354 (16): 1706-1717
  18. Biaggioni I. J Investig Med 2003, 51: S370.
  19. Birk et al. Cephalalgia 2005; 25: 369-377
  20. Boysen et al. Stroke 1984, 15: 241-243.
  21. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211-1215.
  22. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
  23. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29: 415-421.
  24. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-59.
  25. Candelise et al. Lancet 2007; 369: 299-305.
  26. CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339
  27. Chang et al. Cerebrovasc Dis 2006; 22: 258–262.
  28. Chua et al. Neurol J Southeast Asia 2003; 8: 9–13
  29. Coull et al. BMJ 2004; 328: 326-328.
  30. Derendorf et al. J Clin Pharmacol 2005;45: 845–850.
  31. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
  32. Diener Sacco, Yusuf. Cerebrovasc Dis 2007;23: 368-380
  33. Diener et al. Akt Neurol 2007; 34: 8-12.
  34. Diener et al. Cerebrovasc Dis. 2004;17(2-3):253-61
  35. Diener et al. Lancet 2004; 364: 331-337.
  36. Diener et al. Int J Clin Pract 2001; 55: 162–163.
1|2|3 next